Cytoprotective activated protein C averts Nlrp3 inflammasome–induced ischemia-reperfusion injury via mTORC1 inhibition

Blood

Volumn 130, Issue 24, 2017, Pages 2664-2677

  Nazir, Sumra ^a   Gadi, Ihsan ^a   Al Dabet, Moh'd Mohanad ^a   Elwakiel, Ahmed ^a   Kohli, Shrey ^a   Ghosh, Sanchita ^a   Manoharan, Jayakumar ^a   Ranjan, Satish ^a   Bock, Fabian ^a,b   Braun Dullaeus, Ruediger C ^a   Esmon, Charles T ^c,d   Huber, Tobias B ^e   Camerer, Eric ^f   Dockendorff, Chris ^g   Griffin, John H ^h   Isermann, Berend ^a   Shahzad, Khurrum ^a,i  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^g Marquette University   (United States)

^h SCRIPPS RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF SARGODHA   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CRYOPYRIN; CYTOPROTECTIVE AGENT; INFLAMMASOME; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; ANTICOAGULANT AGENT; PROTECTIVE AGENT; PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE; CELL PROTECTION; CONTROLLED STUDY; ENZYME INHIBITION; GENE MUTATION; HEART FIBROBLAST; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; KIDNEY ISCHEMIA; MACROPHAGE; MOUSE; MTOR SIGNALING; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOBLOTTING; KIDNEY; KNOCKOUT MOUSE; METABOLISM; NEWBORN; REPERFUSION INJURY; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; ANTICOAGULANTS; APOPTOSIS; CELLS, CULTURED; CYTOPROTECTION; IMMUNOBLOTTING; INFLAMMASOMES; KIDNEY; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTECTIVE AGENTS; PROTEIN C; RECEPTOR, PAR-1; REPERFUSION INJURY;

EID: 85031715669     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-782102     Document Type: Article

References (67)

1. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol. 2011;8(5):292-300.
2. Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP. The innate immune response in reperfused myocardium. Cardiovasc Res. 2012;94(2):276-283.
3. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1): 126-144.
4. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008; 117(20):2670-2683.
5. Salloum FN, Chau V, Varma A, et al. Anakinra in experimental acute myocardial infarction–does dosage or duration of treatment matter? Cardiovasc Drugs Ther. 2009;23(2):129-135.
6. Sandanger Ø, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013;99(1): 164-174.
7. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594-604.
8. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011; 108(49):19725-19730.
9. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677-687.
10. Patti G, D’Ambrosio A, Mega S, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43(1):35-38.
11. Airaghi L, Lettino M, Manfredi MG, Lipton JM, Catania A. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am Heart J. 1995;130(2):204-211.
12. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev. 1997;8(4):253-265.
13. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18): 1746-1760.
14. Völkers M, Konstandin MH, Doroudgar S, et al. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation. 2013;128(19): 2132-2144.
15. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015; 125(19):2898-2907.
16. Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev. 2012;3:CD004388.
17. Pirat B, Muderrisoglu H, Unal MT, et al. Recombinant human-activated protein C inhibits cardiomyocyte apoptosis in a rat model of myocardial ischemia-reperfusion. Coron Artery Dis. 2007;18(1):61-66.
18. Maehata Y, Miyagawa S, Sawa Y. Activated protein C has a protective effect against myocardial I/R injury by improvement of endothelial function and activation of AKT1. PLoS One. 2012;7(8):e38738.
19. Loubele ST, Spek CA, Leenders P, et al. Activated protein C protects against myocardial ischemia/ reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):1087-1092.
20. Ding JW, Tong XH, Yang J, et al. Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. J Korean Med Sci. 2010; 25(11):1609-1615.
21. Wang J, Yang L, Rezaie AR, Li J. Activated protein C protects against myocardial ischemic/ reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost. 2011;9(7): 1308-1317.
22. Sopel MJ, Rosin NL, Falkenham AG, et al. Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice. PLoS One. 2012;7(9):e45663.
23. Vince JE, Silke J. The intersection of cell death and inflammasome activation. Cell Mol Life Sci. 2016;73(11-12):2349-2367.
24. Bock F, Shahzad K, Wang H, et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA. 2013;110(2): 648-653.
25. Dong W, Wang H, Shahzad K, et al. Activated protein C ameliorates renal ischemia-reperfusion injury by restricting Y-box binding protein-1 ubiquitination. J Am Soc Nephrol. 2015;26(11): 2789-2799.
26. Madhusudhan T, Wang H, Straub BK, et al. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood. 2012;119(3): 874-883.
27. Xu J, Ji Y, Zhang X, Drake M, Esmon CT. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost. 2009;7(5):851-856.
28. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104(6):1740-1744.
29. Wang Y, Zhao Z, Chow N, et al. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke. 2013;44(12): 3529-3536.
30. Kaneider NC, Leger AJ, Agarwal A, et al. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8(12): 1303-1312.
31. Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation. 2009; 120(9):774-784.
32. Aisiku O, Peters CG, De Ceunynck K, et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood. 2015;125(12):1976-1985.
33. Dockendorff C, Aisiku O, Verplank L, et al. Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor. ACS Med Chem Lett. 2012;3(3): 232-237.
34. Shahzad K, Bock F, Al-Dabet MM, et al. Caspase-1, but not caspase-3, promotes diabetic nephropathy. J Am Soc Nephrol. 2016;27(8): 2270-2275.
35. Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. 2008;2008:pdb.prot5080.
36. Finsen AV, Lunde IG, Sjaastad I, et al. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway. PLoS One. 2011;6(12):e28302.
37. Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol. 2014;109(6):444.
38. Toldo S, Mezzaroma E, McGeough MD, et al. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res. 2015;105(2): 203-212.
39. Xie M, Yu Y, Kang R, et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat Commun. 2016;7: 13280.
40. Moon JS, Hisata S, Park MA, et al. mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. Cell Reports. 2015;12(1):102-115.
41. Howell JJ, Hellberg K, Turner M, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2): 463-471.
42. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012; 120(26):5237-5246.
43. Kim HJ, Lee DW, Ravichandran K, et al. NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther. 2013;346(3): 465-472.
44. Szeto HH, Liu S, Soong Y, et al. Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD. J Am Soc Nephrol. 2017;28(5): 1437-1449.
45. Minutoli L, Puzzolo D, Rinaldi M, et al. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury. Oxid Med Cell Longev. 2016;2016:2183026.
46. Lyden P, Levy H, Weymer S, et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des. 2013;19(42):7479-7485.
47. Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J. 2014; 55(2):101-105.
48. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276(14): 11199-11203.
49. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013; 13(6):397-411.
50. van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2017;38(11):828-836.
51. Kovacs P, Bak I, Szendrei L, et al. Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6): 501-507.
52. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000;130(2):197-200.
53. Bracey NA, Gershkovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem. 2014;289(28): 19571-19584.
54. Shigeoka AA, Mueller JL, Kambo A, et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol. 2010;185(10): 6277-6285.
55. Ikeda U, Ikeda M, Kano S, Shimada K. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovasc Pharmacol. 1994;23(4):647-652.
56. Grundmann S, Bode C, Moser M. Inflammasome activation in reperfusion injury: friendly fire on myocardial infarction? Circulation. 2011;123(6): 574-576.
57. Moon JS, Nakahira K, Chung KP, et al. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med. 2016;22(9):1002-1012.
58. Kezic A, Becker JU, Thaiss F. The effect of mTOR-inhibition on NF-kB activity in kidney ischemia-reperfusion injury in mice. Transplant Proc. 2013;45(5):1708-1714.
59. Huang L, Dai K, Chen M, et al. The AMPK agonist PT1 and mTOR inhibitor 3HOI-BA-01 protect cardiomyocytes after ischemia through induction of autophagy. J Cardiovasc Pharmacol Ther. 2016;21(1):70-81.
60. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017; 168(6):960-976.
61. Dalle Pezze P, Sonntag AG, Thien A, et al. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation. Sci Signal. 2012;5(217):ra25.
62. Yamaji K, Wang Y, Liu Y, et al. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res. 2005;115(4): 319-325.
63. Baltzer C, Tiefenböck SK, Frei C. Mitochondria in response to nutrients and nutrient-sensitive pathways. Mitochondrion. 2010;10(6):589-597.
64. Darzynkiewicz Z, Zhao H, Halicka HD, et al. In search of antiaging modalities: evaluation of mTOR- and ROS/DNA damage-signaling by cytometry. Cytometry A. 2014;85(5): 386-399.
65. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie. 2011; 31(3):185-195.
66. Burnier L, Mosnier LO. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. Blood. 2013; 122(5):807-816.
67. Butts B, Gary RA, Dunbar SB, Butler J. The importance of NLRP3 inflammasome in heart failure. J Card Fail. 2015;21(7): 586-593.